Adcetris bags its eighth approval, while SpringWorks and Ono also feature.

One step forward, two steps back for biotech.

Another SERD catalyst and the son of Darzalex take centre stage.

Tough equity markets as well as competitor developments prompt a narrowed focus.

Giredestrant will soon become the first oral SERD to yield first-line data.

The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.